Incyte | INCY - Des Atouts

Prix De L'Action
99.14
Variation Quotidienne
1.40 1.43%
Mensuellement
9.75%
Annuel
58.22%
Q2 Prévisions
92.62




Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agenus USD 226.8M 7.09M 2025-12
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amgen USD 90.59B 445M 2025-12
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
MacroGenics USD 256.85M 13.92M 2025-12
Merck USD 129.55B 12.02B 2025-09
Moderna USD 12.34B 203M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12